Vanguard Group Inc. Cuts Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Vanguard Group Inc. decreased its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,158,084 shares of the biopharmaceutical company's stock after selling 62,036 shares during the quarter. Vanguard Group Inc. owned approximately 6.97% of Dynavax Technologies worth $116,949,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company's stock worth $14,750,000 after buying an additional 32,347 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Dynavax Technologies by 4.4% during the 4th quarter. Bank of New York Mellon Corp now owns 931,328 shares of the biopharmaceutical company's stock valued at $11,893,000 after acquiring an additional 39,513 shares during the period. Nordea Investment Management AB increased its stake in shares of Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after purchasing an additional 232,690 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in Dynavax Technologies by 1.8% in the 4th quarter. Peregrine Capital Management LLC now owns 654,620 shares of the biopharmaceutical company's stock worth $8,359,000 after purchasing an additional 11,687 shares during the period. Finally, Principal Financial Group Inc. lifted its position in Dynavax Technologies by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 596,590 shares of the biopharmaceutical company's stock valued at $7,618,000 after purchasing an additional 18,863 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on DVAX shares. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and lowered their price target for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Trading Up 2.6 %

Dynavax Technologies stock traded up $0.28 during mid-day trading on Friday, hitting $11.25. The company's stock had a trading volume of 2,119,183 shares, compared to its average volume of 2,210,828. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The stock has a market cap of $1.40 billion, a PE ratio of 62.50 and a beta of 1.26. The company has a 50 day moving average of $13.20 and a 200-day moving average of $12.59. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The company had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.